Membrane Sealant Poloxamer P188 Protects Against Isoproterenol Induced Cardiomyopathy in Dystrophin Deficient Mice by Christopher F Spurney et al.
RESEARCH ARTICLE Open Access
Membrane Sealant Poloxamer P188 Protects
Against Isoproterenol Induced Cardiomyopathy
in Dystrophin Deficient Mice
Christopher F Spurney1,2,3, Alfredo D Guerron3, Qing Yu3, Arpana Sali3, Jack H van der Meulen3, Eric P Hoffman2,3
and Kanneboyina Nagaraju2,3*
Abstract
Background: Cardiomyopathy in Duchenne muscular dystrophy (DMD) is an increasing cause of death in patients.
The absence of dystrophin leads to loss of membrane integrity, cell death and fibrosis in cardiac muscle. Treatment
of cardiomyocyte membrane instability could help prevent cardiomyopathy.
Methods: Three month old female mdx mice were exposed to the b1 receptor agonist isoproterenol
subcutaneously and treated with the non-ionic tri-block copolymer Poloxamer P188 (P188) (460 mg/kg/dose i.p.
daily). Cardiac function was assessed using high frequency echocardiography. Tissue was evaluated with Evans Blue
Dye (EBD) and picrosirius red staining.
Results: BL10 control mice tolerated 30 mg/kg/day of isoproterenol for 4 weeks while death occurred in mdx mice
at 30, 15, 10, 5 and 1 mg/kg/day within 24 hours. Mdx mice tolerated a low dose of 0.5 mg/kg/day. Isoproterenol
exposed mdx mice showed significantly increased heart rates (p < 0.02) and cardiac fibrosis (p < 0.01) over
4 weeks compared to unexposed controls. P188 treatment of mdx mice significantly increased heart rate (median
593 vs. 667 bpm; p < 0.001) after 2 weeks and prevented a decrease in cardiac function in isoproterenol exposed
mice (Shortening Fraction = 46 ± 6% vs. 35 ± 6%; p = 0.007) after 4 weeks. P188 treated mdx mice did not show
significant differences in cardiac fibrosis, but demonstrated significantly increased EBD positive fibers.
Conclusions: This model suggests that chronic intermittent intraperitoneal P188 treatment can prevent
isoproterenol induced cardiomyopathy in dystrophin deficient mdx mice.
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Background
Since cardiomyopathy is an increasing cause of morbid-
ity and mortality in Duchenne muscular dystrophy
(DMD) patients, pre-clinical drug trials in mice are an
important initial step to investigate potential therapeutic
pathways for the treatment of DMD cardiomyopathy
[1]. However, previous studies in mdx mice show that
the cardiomyopathy develops slowly and only becomes
evident by non-invasive echocardiography around 9
months of age [2,3]. Mdx mice are asymptomatic from a
cardiac standpoint at this age and show no signs of
heart failure throughout their life. This mild phenotype
can make it difficult to measure significant cardiac end-
points for pre-clinical drug studies and requires 6 to 12
month long treatment duration, making these trials very
expensive, time consuming and cumbersome [4].
In an attempt to hasten the phenotype, many investiga-
tors use short treatment courses with invasive models of
cardiac stress including cardiac cannulation with dobuta-
mine or isoproterenol infusion and aortic banding [5-10].
These studies confirm that untreated mdx mice do not
tolerate cardiac stress normally due to the lack of dystro-
phin in cardiac muscle. This inability to handle stress is
thought to be related to membrane instability from the
loss of dystrophin. Experiments by Yasuda et al. (2005)
showed that intact, isolated dystrophin-deficient cardiac
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myocytes have reduced compliance and increased
susceptibility to stretch-mediated calcium overload, lead-
ing to cell contracture and death [9].
Improvement of membrane stability is one potential
therapeutic pathway in DMD. Poloxamer 188 (P188) is
known to stabilize red blood cell membranes in sickle
cell disease [11]. P188 is a non-ionic triblock co-poly-
mer, poly(ethylene oxide)80-poly(propylene oxide)27-poly
(ethylene oxide)80, shown to insert into artificial lipid
monolayers and repair damaged biological membranes.
Based on these properties, Yasuda et al. (2005) studied
P188 in the dystrophin deficient mdx mouse heart using
an open chest protocol with a catheter in the left ventri-
cle. This model showed that administration of P188 dur-
ing dobutamine infusion prevented the development of
acute cardiac failure [9].
In this study, we use chronic, intermittent dosing of
P188 with a continuous, low dose isoproterenol cardiac
stress model and non-invasive assessment of cardiac
function. Mdx mice only tolerated significantly reduced
isoproterenol concentrations compared to wild type
mice and developed decreased shortening fraction and
increased cardiac fibrosis over 4 weeks. Treatment with
P188 may prevent the decrease in shortening fraction
during isoproterenol exposure compared to untreated
mdx mice.
Current therapies for cardiomyopathy in DMD are
non-specific, but P188 directly targets membrane
instability which is known to be one of the major patho-
logical defects in dystrophin deficient cells. These
experiments show that chronic, intermittent P188 dos-
ing may provide a potential direct therapy for cardio-
myopathy in Duchenne muscular dystrophy.
Methods
Animal care
The investigation conforms to the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-
23, revised 1985). All mice were handled according to
the Institutional Animal Care and Use Committee
guidelines (protocol #01002). Generally, 2-3 month old
female C57BL/10ScSn-Dmdmdx/J (mdx) and C57BL/
10ScSn (wild type) mice weighing 20-25 grams were
purchased from the Jackson Laboratory (Bar Harbor,
Ma). All mice were housed in an individually vented
cage system with a 12 hour light-dark cycle and received
standard mouse chow and purified water ad libitum.
Drug treatment
Subcutaneous pumps containing isoproterenol (Sigma, St.
Louis, Mo) diluted in normal saline at doses of 30, 15, 10,
5, 1 or 0.5 mg/kg/day were implanted in mice. Mice also
received daily intraperitoneal injections of either normal
saline (0.2 cc) or 460 mg/kg/dose of P188 (BASF Corpora-
tion, Florham Park, NJ) in normal saline (0.2 cc) [12]. Two
separate trials of 2 and 4 weeks duration were performed.
Mice received the initial injection prior to osmotic pump
implantation. Mice were injected in the morning except
during echocardiography measurements when injections
were performed immediately after imaging.
Subcutaneous pump insertion
The Alzet 2004 osmotic pump (Durect Corporation,
Cupertino, Ca) (200 microliter reservoir with a delivery
rate of 0.25 microliters/hour) was filled with the appropri-
ate isoproterenol solution and allowed to equilibrate for
approximately 40 hours in normal saline per manufac-
turer’s recommendations prior to implantation. Mice were
anesthetized using approximately 3% inhaled isoflurane
delivered via a nose cone with a passive exhaust system. A
small area on the back of the mouse, slightly posterior to
the scapulae, was shaved and surgically prepped using
betadine and alcohol solutions. A small 1-2 cm incision
was made in the midscapular region. A hemostat was
inserted and gently opened and closed to create a pocket
for the pump, approximately 1 cm longer and wider than
the pump to allow for some free movement. An osmotic
pump was inserted with the exit port entering the pocket
first. The incision was closed with 2-3 sutures.
Echocardiography
Mice were anesthetized with 1-2% isoflurane in 100%
oxygen and scanning was performed over 20 minutes
using a high frequency ultrasound probe (RMZ 702a,
Vevo 660, VisualSonics, Toronto, Canada) as previously
described [3]. Qualitative and quantitative measurements
were made offline using analytic software (VisualSonics,
Toronto, Canada). A blood pressure (BP) cuff was
placed around the tail and the tail was then placed in a
sensor assembly for non-invasive blood pressure moni-
toring (SC1000, Hatteras Instruments, Cary, NC). Ten
consecutive blood pressure measurements were obtained
and the average pressure used for each mouse.
In vitro skeletal muscle force contraction
Experiments were conducted on the extensor digitorum
longus (EDL) muscle of the right hindlimb of mice as
previously described [13]. The muscle length was mea-
sured with calipers and the optimal fiber length calcu-
lated by multiplying the optimal muscle length by 0.45,
the established fiber length/muscle length ratio for EDL
muscle [14]. The muscle mass was weighed after
removal of the muscle from the bath. The muscle speci-
fic force, a measure of intrinsic force generation of mus-
cle, was calculated using the maximal isometric force,
the muscle mass and the fiber length according the fol-
lowing equation: specific force = maximal isometric
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force/[muscle mass × (density of muscle tissue * fiber
length)-1]. Muscle tissue density used was 1.056 kg/L.
Collagen quantification
Five paraffin sections of cardiac tissue (7 um thickness)
were stained with picrosirius red (Histoserv, Gaithersburg,
Md). The tissue was magnified under a light microscope
at an objective of 4X and a digital image of the entire sec-
tion was obtained using computer software (Olympus C.A.
S.T. Stereology System, Olympus America Inc., Center
Valley, PA). These digital images were processed using
Image J (NIH) with additional threshold color plug-ins to
process jpeg images. Pixels corresponding to the area
stained in red in the previously described technique were
normalized to the total pixel area of the tissue image and
the results were expressed as percent of collagen. Images
were analyzed by two independent, blinded investigators.
Evans Blue Dye (EBD) quantification
Three mice per group received an intra-peritoneal injec-
tion of 1% EBD in normal saline (Sigma, St. Louis, Mo) at
a dose of 100 microliters per 10 grams body weight. Less
than 18 hours after injection, the mice were sacrificed and
the heart tissue snap-frozen in isopentane cooled with
liquid nitrogen and stored at -80°C. The tissue was cut
into 7 micrometer thick sections and incubated in ice-cold
acetone at -20°C for 3 minutes and mounted using Vecta-
shield (Vector Laboratories, Burlingame, CA). Slides were
examined under a Nikon Eclipse fluorescent microscope
using Texas Red filter and fibers showing red fluorescence
were counted over the entire heart tissue slice by two
independent, blinded investigators and expressed as abso-
lute number of EBD positive fibers per heart.
Statistical analysis
At each time point, normality was tested for each mea-
surement using the Shipiro-Wilk normality test. Those
having a normal distribution were analyzed using a
parametric t-test (Table 1) or an one way ANOVA with
adjustment of pair-wise post hoc tests for multiple com-
parisons using the Sidak method (Tables 2 and 3). For
those measurements not conforming to normality, non-
parametric tests were used. At time 0, comparisons
between BL10 and MDX untreated mice used a Wil-
coxon rank sum test to compare medians (Table 4). At
time 2 and 4, comparisons between all 5 treatment
groups used a Kruskal-Wallis test to compare medians
(Tables 5 and 6). For comparisons with a significant
overall p-value from the Kruskal-Wallis test, individual
post-hoc pair-wise comparisons were done using a Wil-
coxon rank sum test. All p-values from post-hoc tests
were adjusted for multiple comparisons using the Sidak
method. P-values presented in Tables 5 and 6 are Sidak
adjusted p-values. Specific muscle force testing was
analyzed using a one-way ANOVA. Percent collagen
was analyzed using Kruskal-Wallis test with Dunn’s
post-hoc comparisons. EBD counts were analyzed using
an unpaired t-test. All analyses used a critical p-value of
0.05 to assign significance.
Results
Isoproterenol cardiac stress model in mdx mice
Using a standard dose of isoproterenol (30 mg/kg/day)
known to induce hypertrophy in normal mouse hearts,
all mdx mice died within 12 hours [15-18]. Normal BL10
mice tolerated this dose for 4 weeks. Decreasing doses of
15, 10, 5 and 1 mg/kg/day continued to cause 100% mor-
tality in mdx mice within 24 hours. Treatment with P188
did not prevent mdx mice from dying at doses greater
than 0.5 mg/kg/day. Therefore, all experiments were per-
formed at a dose of 0.5 mg/kg/day. At this dose, 19/20
mice tolerated treatment for two weeks and 14/15 mice
tolerated treatment for 4 weeks. Of the mice that died,
one was in the P188 treated, isoproterenol exposed group
and one was in the isoproterenol only group. No mice
completing the study were excluded from the results
when data was reliably obtained.
Body weights
All the mdx mice started the trial with similar average
weights (g): Isoproterenol exposed and P188 treated
21.3 ± 1.3; isoproterenol exposed and saline treated 21.2
± 1.9; control (saline exposed and saline treated) 20.5 ±
1.5. There were no significant differences in body
weights at the end of 4 weeks of treatment between dif-
ferent groups: isoproterenol exposed and P188 treated
24.8 ± 0.9; isoproterenol exposed and saline treated 24.3
± 1.4; saline exposed and saline treated 23.8 ± 1.86.
Table 1 Baseline parametric comparisons of cardiac
parameters in untreated 10 week old BL10 and mdx
mice
BL10 MDX
Measurement N Mean ± SD N Mean ± SD P-value
Heart rate (bpm) 5 473 ± 35 22 458 ± 48 0.5370
SF% 10 30.91 ± 1.64 9 32.60 ± 3.08 0.1471
EF% 10 56.37 ± 3.65 9 58.38 ± 2.29 0.1739
LVID (d) (mm) 10 4.00 ± 0.16 9 4.05 ± 0.19 0.5776
LVPW (d) (mm) 10 0.54 ± 0.06 9 0.56 ± 0.03 0.4305
LV mass (mg) 10 77.92 ± 8.36 9 72.33 ± 4.67 0.0945
AoV vel (mm/s) 5 1079 ± 138 9 969 ± 121 0.1439
Systolic BP (mmHg) 5 89 ± 6 22 73 ± 6 <0.0001
Bpm - beats per minute; SF% - shortening fraction percent; EF% - ejection
fraction percent; LVID(d) - left ventricular internal diameter in diastole; LVPW
(d) - left ventricular posterior wall thickness in diastole; LV - left ventricle; AoV
vel - aortic valve velocity; BP - blood pressure; mmHg - millimeters of
mercury; SD - standard deviation; mm - millimeters; mm/s - millimeters per
second; mg - milligrams.
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Cardiovascular function
Results are presented in Tables 1, 2, 3, 4, 5 and 6. Baseline
data was performed prior to osmotic pump implantation.
Heart rate
There was no significant difference between heart rates
of control (saline exposure and saline treatment) BL10
and mdx mice at baseline, 2 weeks or 4 weeks. After 2
weeks of exposure, isoproterenol significantly increased
the hearts rates in mdx mice (p = 0.03) compared to
untreated controls. Mdx mice exposed to isoproterenol
and treated with P188 also had significantly increased
heart rates compared to mdx mice exposed to isoproter-
enol only (p = 0.001). After 4 weeks of exposure, isopro-
terenol treated mdx mice had significantly increased
heart rates compared to untreated controls (p < 0.02).
Systolic function
There was no significant difference between control
BL10 and control mdx mice in shortening fraction (SF)
or ejection fraction (EF) at baseline, 2 weeks or 4 weeks.
Isoproterenol exposure significantly increased systolic
Table 2 Parametric comparisons of cardiac parameters after 2 weeks of exposure to isoproterenol and treatment with
P188 in BL10 and mdx mice
Measurement Group N Mean ± SD Overall p-value Significantly different groups
SF% BL10 - Untx 3 31.47 ± 0.56 BL10-Untx vs. BL10-Iso (p < 0.001)
BL10 - Iso 7 49.33 ± 3.87 <0.0001 BL10-Untx vs. MDX-Iso+P188 (p = 0.001)
BL10-Iso vs. MDX-Untx (p < 0.001)
MDX - Untx 6 30.31 ± 2.50 BL10-Iso vs. MDX-Iso (p < 0.001)
MDX - Iso 10 38.06 ± 4.81 BL10-Iso vs. MDX-Iso+P188 (p = 0.019)
MDX - Iso + P188 9 42.95 ± 3.27 MDX-Untx vs. MDX-Iso (p = 0.003)
MDX-Untx vs. MDX-Iso+P188 (p < 0.001)
LVID (d) (mm) BL10 - Untx 3 4.07 ± 0.35
BL10 - Iso 7 3.70 ± 0.14
MDX - Untx 6 3.84 ± 0.27 0.0011 BL10-Untx vs. MDX-Iso+P188 (p = 0.007)
MDX-Untx vs. MDX-Iso+P188 (p = 0.030)
MDX - Iso 10 3.42 ± 0.37
MDX - Iso + P188 9 3.37 ± 0.22
LVPW (d) (mm) BL10 - Untx 3 0.56 ± 0.01 BL10-Untx vs. BL10-Iso (p = 0.001)
BL10 - Iso 7 0.85 ± 0.07 BL10-Untx vs. MDX-Iso (p = 0.001)
MDX - Untx 6 0.60 ± 0.09 <0.0001 BL10-Untx vs. MDX-Iso+P188 (p < 0.001)
BL10-Iso vs. MDX-Untx (p = 0.001)
MDX - Iso 10 0.88 ± 0.14 MDX-Untx vs. MDX-Iso (p < 0.001)
MDX - Iso + P188 9 0.94 ± 0.07 MDX-Untx vs. MDX-Iso+P188 (p < 0.001)
LV mass (mg) BL10 - Untx 3 77.48 ± 1.60 BL10-Untx vs. BL10-Iso (p = 0.002)
BL10 - Iso 7 105.7 ± 12.22 BL10-Iso vs. MDX-Untx (p < 0.001)
MDX - Untx 6 73.16 ± 9.55 <0.0001 BL10-Iso vs. MDX-Iso (p < 0.001)
MDX - Iso 10 81.84 ± 9.62 BL10-Iso vs. MDX-Iso+P188 (p = 0.003
MDX - Iso + P188 9 85.26 ± 9.21
AoV vel (mm/s) BL10 - Untx 3 1107 ± 49
BL10 - Iso 7 1194 ± 152 BL10-Iso vs. MDX-Iso (p = 0.003)
MDX - Untx 6 943 ± 67 <0.0001 MDX-Untx vs. MDX-Iso+P188 (p = 0.001)
MDX - Iso 10 885 ± 195 MDX-Iso vs. MDX-Iso+P188 (p < 0.001)
MDX - Iso + P188 9 1317 ± 150
Systolic BP (mmHg) BL10 - Untx 3 92 ± 6
BL10 - Iso 7 107 ± 5 BL10-Iso vs. MDX-Untx (p = 0.023)
MDX - Untx 3 88 ± 3 0.0005 BL10-Iso vs. MDX-Iso (p < 0.001)
MDX - Iso 5 82 ± 5 BL10-Iso vs. MDX-Iso+P188 (p = 0.031)
MDX - Iso + P188 6 92 ± 13
SF% - shortening fraction percent; LVID(d) - left ventricular internal diameter in diastole; LVPW(d) - left ventricular posterior wall thickness in diastole; LV - left
ventricle; AoV vel - aortic valve velocity; BP - blood pressure; mmHg - millimeters of mercury; SD - standard deviation; mm - millimeters; mm/s - millimeters per
second; mg - milligrams; iso - isoproterenol; untx - untreated.
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Table 3 Parametric comparisons of cardiac parameters after 4 weeks of exposure to isoproterenol and treatment with
P188 in BL10 and mdx mice
Measurement Group N Mean ± SD Overall p-value Significantly different groups
SF% BL10 - Untx 3 33.34 ± 1.15 BL10-Untx vs. BL10-Iso (p = 0.019)
BL10-Untx vs. MDX-Iso+P188 (p = 0.017)
BL10 - Iso 7 45.13 ± 4.71 BL10-Iso vs. MDX-Untx (p < 0.001)
MDX - Untx 6 29.64 ± 3.11 <0.0001 BL10-Iso vs. MDX-Iso (p = 0.006)
MDX - Iso 9 35.37 ± 5.77 MDX-Untx vs. MDX-Iso+P188 (p < 0.001)
MDX - Iso + P188 5 45.97 ± 6.23 MDX-Iso vs. MDX-Iso+P188 (p = 0.007)
EF% BL10 - Untx 3 59.15 ± 1.89
BL10 - Iso 7 69.72 ± 5.56
MDX - Untx 6 57.25 ± 7.78 0.0027 BL10-Iso vs. MDX-Untx (p = 0.020)
MDX - Iso 9 57.84 ± 4.56 BL10-Iso vs. MDX-Iso (p = 0.013)
MDX - Iso + P188 5 68.28 ± 9.89
LVID (d) (mm) BL10 - Untx 3 4.03 ± 0.12
BL10 - Iso 7 3.73 ± 0.13 BL10-Untx vs. MDX-Iso+P188 (p = 0.002)
MDX - Untx 6 4.02 ± 0.07 0.0001 BL10-Iso vs. MDX-Iso (p = 0.029)
MDX - Iso 9 3.54 ± 0.34 MDX-Untx vs. MDX-Iso (p = 0.0125)
MDX - Iso + P188 5 3.27 ± 0.32 MDX-Untx vs. MDX-Iso+P188 (p < 0.001)
LVPW (d) (mm) BL10 - Untx 3 0.62 ± 0.10
BL10 - Iso 7 0.80 ± 0.08 BL10-Untx vs. BL10-Iso (p = 0.022)
MDX - Untx 6 0.59 ± 0.01 <0.0001 BL10-Untx vs. MDX-Iso (p = 0.001)
BL10-Untx vs. MDX-Iso+P188 (p = 0.004)
MDX - Iso 9 0.86 ± 0.09 BL10-Iso vs. MDX-Untx (p < 0.001)
MDX - Iso + P188 5 0.84 ± 0.07 MDX-Untx vs. MDX-Iso (p < 0.001) MDX-Untx vs. MDX-Iso+P188
(p < 0.001)
LV mass (mg) BL10 - Untx 3 75.16 ± 7.16
BL10 - Iso 7 98.33 ± 11.06
MDX - Untx 6 76.88 ± 3.36 0.0019 BL10-Untx vs. BL10-Iso (p = 0.012)
MDX - Iso 9 87.22 ± 11.08 BL10-Iso vs. MDX-Untx (p = 0.003)
MDX - Iso + P188 5 89.15 ± 7.54
AoV vel (mm/s) BL10 - Untx 3 1004 ± 87
BL10 - Iso 7 1077 ± 186
MDX - Untx 6 1105 ± 117 0.0388 None
MDX - Iso 9 1274 ± 159
MDX - Iso + P188 5 1253 ± 183
Systolic BP (mmHg) BL10 - Untx 3 94 ± 5
BL10 - Iso 7 99 ± 8 BL10-Untx vs. MDX-Iso (p = 0.011)
MDX - Untx 3 87 ± 8 0.0001 BL10-Iso vs. MDX-Iso (p < 0.001)
MDX - Iso 9 73 ± 11 BL10-Iso vs. MDX-Iso+P188 (p = 0.006)
MDX - Iso + P188 4 77 ± 6
Diastolic BP (mmHg) BL10 - Untx 3 50 ± 9
BL10 - Iso 7 85 ± 8
MDX - Untx 3 67 ± 3 <0.0001 BL10-Untx vs. BL10-Iso (p < 0.001)
BL10-Iso vs. MDX-Untx (p = 0.022)
MDX - Iso 9 61 ± 8 BL10-Iso vs. MDX-Iso (p < 0.001)
MDX - Iso + P188 4 58 ± 3 BL10-Iso vs. MDX-Iso+P188 (p < 0.001)
Mean BP (mmHg) BL10 - Untx 3 64 ± 7
BL10 - Iso 7 89 ± 7 BL10-Untx vs. BL10-Iso (p < 0.001)
MDX - Untx 3 73 ± 4 <0.0001 BL10-Iso vs. MDX-Untx (p = 0.018)
Spurney et al. BMC Cardiovascular Disorders 2011, 11:20
http://www.biomedcentral.com/1471-2261/11/20
Page 5 of 10
function measured via SF in BL10 mice at 2 weeks (p <
0.001) and 4 weeks (p = 0.02) compared to strain
matched untreated control mice. Mdx mice exposed to
isoproterenol showed significantly increased SF at 2
weeks compared to untreated mdx controls (p = 0.03).
(Figure 1) P188 treatment significantly improved SF
compared to untreated, isoproterenol exposed mdx mice
at 4 weeks (p = 0.007). (Figure 2) At 2 weeks, indepen-
dent 2-D measures of EF showed significant increases in
P188 treated, isoproterenol exposed mdx mice com-
pared to isoproterenol exposed mdx mice (p < 0.001).
At 4 weeks, EF agreed with SF measures and showed no
difference between control and isoproterenol treated
mdx mice.
Left ventricular dimensions and mass
There were no significant differences in left ventricular
dimensions or mass between control BL10 and mdx
mice at baseline, 2 and 4 weeks. The left ventricular
internal diameter measured in diastole [LVID(d)] signifi-
cantly decreased in P188 treated, isoproterenol exposed
mdx mice at 2 weeks compared to untreated mdx con-
trols (p = 0.03). At 4 weeks, LVID(d) was also signifi-
cantly decreased in isoproterenol exposed mdx mice (p
< 0.02) and in P188 treated, isoproterenol exposed mdx
mice (p < 0.001) compared to untreated mdx controls.
Isoproterenol exposure led to an increase in the dimen-
sion of the left ventricular posterior wall in diastole
[LVPW(d)] in BL10 and mdx mice at 2 and 4 weeks of
treatment (p < 0.03) compared to untreated strain
matched controls. P188 treatment did not significantly
affect LVPW(d). This increase in wall thickness was cor-
related with 2-D left ventricular mass (LV mass) mea-
sures. LV mass was significantly increased after 2 and 4
weeks of isoproterenol exposure in BL10 mice only (p <
0.02).
Aortic valve maximum velocity
Aortic valve peak velocity did not significantly differ
between control BL10 and mdx mice at baseline, 2 and
4 weeks. At 2 weeks of isoproterenol exposure, aortic
velocity was significantly increased in mdx mice treated
with P188 compared to untreated isoproterenol exposed
mdx mice (p < 0.001), but this difference was not seen
after 4 weeks of treatment when the two groups had
similar velocities.
Blood pressure
Mdx mice showed significantly decreased systolic and
mean blood pressures at baseline compared to BL10
mice (p < 0.005). Mdx mice did not show a significant
increase in blood pressure after isoproterenol exposure
compared to unexposed controls. P188 treatment did
not significant affect blood pressure measurements.
In vitro skeletal muscle strength
(Additional file 1) After two weeks of exposure to iso-
proterenol in the mdx mouse (n = 5), the specific force
(sPo) was 151 ± 25 kN/m2 in the EDL. In mdx mice
exposed to isoproterenol and treated with P188 (n = 5),
the sPo was 176 ± 12 kN/m2 and not significantly differ-
ent. There was also no significant difference after 4
weeks. Mdx mice exposed to isoproterenol (n = 5) had a
sPo of 201 ± 36 kN/m2 and mdx mice exposed to iso-
proterenol and treated with P188 had a sPo 185 ± 25 of
kN/m2 (p = 0.5). Mdx mice unexposed to isoproterenol/
P188 (n = 3) had a sPo of 167 ± 14 of kN/m2 and did
not differ significantly from the other groups.
Percent cardiac collagen content
There was no significant collagen content/fibrosis found
in BL10 hearts. Mdx hearts exposed to isoproterenol
only for 2 weeks showed 1.4 ± 1.1% fibrosis and those
hearts exposed to isoproterenol and treated with P188
showed 1.3 ± 1.1% fibrosis. After 4 weeks of isoprotere-
nol exposure, mdx hearts showed 3.0 ± 2.8% and those
hearts exposed to isoproterenol and treated with P188
showed 2.9 ± 2.1% fibrosis (Figure 3). Mdx control mice
showed 1.1 ± 0.4% after 4 weeks, thus there was a
Table 3 Parametric comparisons of cardiac parameters after 4 weeks of exposure to isoproterenol and treatment with
P188 in BL10 and mdx mice (Continued)
MDX - Iso 9 63 ± 7 BL10-Iso vs. MDX-Iso (p < 0.001)
MDX - Iso + P188 4 64 ± 2 BL10-Iso vs. MDX-Iso+P188 (p < 0.001)
SF% - shortening fraction percent; EF% - ejection fraction percent; LVID(d) - left ventricular internal diameter in diastole; LVPW(d) - left ventricular posterior wall
thickness in diastole; LV - left ventricle; AoV vel - aortic valve velocity; BP - blood pressure; mmHg - millimeters of mercury; SD - standard deviation; mm -
millimeters; mm/s - millimeters per second; mg - milligrams; iso - isoproterenol; untx - untreated.
Table 4 Baseline non-parametric comparisons in
untreated 10 week old BL10 and mdx mice
BL10 MDX




5 50 41 -
69
22 42 32 -
69
0.0650
Mean BP (mmHg) 5 63 57 -
76
22 51 44 -
76
0.0044
BP - blood pressure; mmHg - millimeters of mercury.
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significant increase in cardiac fibrosis in 4 week exposed
and treated mdx groups (p < 0.05).
Evans Blue Dye (EBD) positive cells
The number of EBD positive cells in the hearts of mdx
mice showed that mice exposed to isoproterenol only
had 5 ± 7 cells compared to 18 ± 15 cells per entire
heart section in P188 treated isoproterenol exposed cells
(p < 0.03). Untreated mdx hearts had no significant EBD
staining at this age (12 weeks).
Discussion
This study shows that chronic, intermittent P188 may be
effective in protecting cardiac function in a subcutaneous
low dose isoproterenol stress model over a 4 week period
in dystrophin deficient hearts. Mdx mice treated with
P188 during exposure to isoproterenol were able to
maintain increased systolic function (46 ± 6 vs. 35 ± 6 SF
%; p < 0.01) compared to untreated isoproterenol
exposed mdx mice suggesting that chronic, intermittent
injections of intraperitoneal P188 can stabilize cardiac
muscle cell membranes in vivo. These results also pro-
vide a model for the development of mild cardiomyopa-
thy and cardiac fibrosis in 2 month old mdx mice over a
period of 4 weeks and allows for quicker screening of
potential drugs targeting cardiac function and fibrosis.
We also showed that mdx mice remain exquisitely
sensitive to in vivo cardiac stress from the beta agonist
Table 5 Non-parametric comparisons of cardiac parameters after 2 weeks of exposure to isoproterenol and treatment
with P188 in BL10 and mdx mice
Measurement Group N Median Range Overall p-value Significantly different groups
Heart rate (bpm) BL10 - Untx 3 451 410 - 466
BL10 - Iso 7 645 593 - 691 BL10-Iso vs. MDX-Untx (p = 0.0267)
MDX - Untx 6 454 416 - 477 0.0001 MDX-Untx vs. MDX-Iso (p = 0.0325)
MDX - Iso 10 593 462 - 632 MDX-Untx vs. MDX-Iso+P188 (p = 0.0129)
MDX - Iso + P188 9 667 632 - 686 MDX-Iso vs. MDX-Iso+P188 (p = 0.0008)
EF% BL10 - Untx 3 60.35 59.17 - 61.32
BL10 - Iso 7 80.03 77.40 - 86.59 BL10-Iso vs. MDX-Untx (p = 0.0267)
MDX - Untx 6 59.00 50.93 - 62.22 0.0001 BL10-Iso vs. MDX-Iso (p = 0.0060)
MDX - Iso 10 65.00 50.15 - 75.10 MDX-Untx vs. MDX-Iso+P188 (p = 0.0149)
MDX - Iso + P188 9 74.85 69.98 - 81.18
Diastolic BP (mmHg) BL10 - Untx 3 74 57 - 86
BL10 - Iso 7 95 83 - 102
MDX - Untx 3 58 39 - 62 0.0026 BL10-Iso vs. MDX-Iso (p = 0.0441)
BL10-Iso vs. MDX-Iso+P188 (p = 0.0267)
MDX - Iso 5 56 50 - 66
MDX - Iso + P188 6 53 44 - 60
Mean BP (mmHg) BL10 - Untx 3 78 67 - 89
BL10 - Iso 7 97 89 - 106
MDX - Untx 3 67 56 - 71 0.0031 BL10-Iso vs. MDX-Iso (p = 0.0431)
BL10-Iso vs. MDX-Iso+P188 (p = 0.0267)
MDX - Iso 5 63 59 - 73
MDX - Iso + P188 6 66 57 - 71
Bpm - beats per minute; EF% - ejection fraction percent; BP - blood pressure; mmHg - millimeters of mercury; SD - standard deviation; iso - isoproterenol; untx -
untreated.
Table 6 Non-parametric comparisons of cardiac parameters after 4 weeks of exposure to isoproterenol and treatment
with P188 in BL10 and mdx mice
Measurement Group N Median Range Overall p-value Significantly different groups
Heart rate (bpm) BL10 - Untx 3 450 421 - 476
BL10 - Iso 7 615 532 - 656
MDX - Untx 6 438 400 - 489 0.0004 BL10-Iso vs. MDX-Untx (p = 0.0267)
MDX - Iso 9 585 541 - 667 MDX-Untx vs. MDX-Iso (p = 0.0149)
MDX - Iso + P188 5 632 615 - 667
Bpm - beats per minute; iso - isoproterenol; untx - untreated.
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administration. All mdx mice died within 24 hours at
doses of 30, 15, 10, 5 and 1 mg/kg/day and could only
tolerate a six-fold decreased isoproterenol dose (0.5 mg/
kg/day) compared to BL10 control mice. Even at this
dosing, mdx mice had a shortening fraction of 42 ± 6%
at 24 hours that decreased to 38 ± 5% at 2 weeks and
35 ± 6% at 4 weeks. P188 treatment did not improve
survival at the higher levels of isoproterenol. This data
suggests that the effectiveness to chronic intraperitoneal
injections of P188 is limited and cannot stabilize cardiac
cells as well as acute, intravenous administration.
P188 was previously studied in dystrophin deficient
animal models and shown to prevent acute cardiac failure
after dobutamine-induced cardiac stress in mdx mice.
These studies utilized acute, intravenous administration
[9]. Using chronic, intermittent dosing, our non-invasive
in vivo cardiac stress model of subcutaneous isoprotere-
nol administration and cardiac assessment using echocar-
diography demonstrated similar results. Yasuda et al.
(2005) concluded that the primary effect of P188 was to
acutely restore myocyte compliance and improve end-
diastolic volumes. While we did not measure these para-
meters, increased systolic function that was equal to
BL10 mice demonstrated an increased capacity to toler-
ate cardiac stress and is likely related to improved myo-
cyte compliance. P188 can also decrease blood viscosity
by stabilizing red blood cell membranes; decreasing red
blood cell adhesion; and improving microvascular blood
flow [19,20]. These changes can decrease effective after-
load and are potential physiological mechanisms that
could improve heart rates and cardiac systolic function in
P188 treated mice.
Townsend et al. (2010) recently reported that a chronic
8 week infusion of P188 (60 mg/kg/h) in golden retriever
muscular dystrophy (GRMD) dogs showed significantly
decreased cardiac fibrosis and prevented ventricular dila-
tion [21]. Our study did not show a significant decrease
in cardiac fibrosis in P188 treated mice (3.0% vs. 2.9%).
This may be related to our single daily dosing protocol
that provided sufficient P188 to partially stabilize some
cardiomyocytes and improve cardiac function, but not
enough to prevent significant myocyte loss and fibrosis.
The GRMD model also shows a more severe, naturally
occurring cardiomyopathy which is difficult to replicate
in the mouse model, even with isoproterenol exposure.
Thus, fibrotic signaling pathways in the GRMD model
were increased compared to the mdx mouse, and P188
therapy showed more significant modulation. The mdx
mouse was so sensitive to isoproterenol stress that we
were unable to test higher doses that could have
increased fibrosis, without mortality, to better evaluate
the anti-fibrotic effectiveness of P188.
Our study also did not show ventricular dilation, but
rather displayed decreased left ventricular internal
dimensions. This was secondary to increased left ventri-
cular wall thickness and mass, seen in both P188 treated
and untreated mice from the increased cardiac workload.
Figure 1 P188 treated, isoproterenol exposed and
isoproterenol exposed mdx mice show significantly increased
percent shortening fraction (%SF) compared to untreated mdx
controls after 2 weeks of therapy.
Figure 2 P188 treated, isoproterenol exposed mdx mice show
significantly increased percent shortening fraction (%SF)
compared to isoproterenol exposed mdx mice and untreated
controls after 4 weeks of therapy.
Figure 3 Representative cross-sectional tissue slices of hearts
stained with picrosirius red show minimal fibrosis in untreated
mdx hearts (mean 1% collagen; Panel A) and significantly
increased fibrosis in mdx hearts exposed to 0.5 mg/kg/day
isoproterenol for 4 weeks (mean 3.0% collagen; Panel B) and
in mdx hearts exposed to 0.5 mg/kg/day isoproterenol and
treated with P188 for 4 weeks (mean 2.9% collagen; Panel C).
Staining is consistent with patchy fibrosis patterns seen in older
mdx mice
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Previous studies have shown both dilated and non-dilated
cardiomyopathy in mdx mice [2,3]. In the presence of
isoproterenol, untreated mdx mice were able to show
cardiac hypertrophy similar to BL10 mice and this is
likely related to compensatory mechanisms that are still
present in the 3 month old mice that become decreased
with age.
We unexpectedly demonstrated a significant increase
in Evan’s blue dye (EBD) positive fibers in P188 treated
mdx hearts. Quilan et al. (2006) also found similar
unexpected results studying skeletal muscles in exer-
cised mdx mice, showing equal or increased %-EBD
penetration in P188 treated rectus femoris muscle [22].
However, although we found an increase in EBD posi-
tive fibers, these hearts showed increased systolic func-
tion compared to untreated hearts. Based on these
findings, we propose that P188 can stabilize mildly
damaged cells, especially at lower effective doses. These
cells remain functional but become EBD positive on his-
tology. Also, there is the potential that P188 facilitates
EBD entry into cells without compromising function.
We showed significantly lower blood pressures in mdx
mice at baseline compared to controls. This was pre-
viously reported in 9 month old mdx mice [3]. P188
treatment had no effect on blood pressure levels, as was
also seen in the study by Townsend et al. (2010) [21].
The mechanism for decreased blood pressures is not
clear at this time and may be related to cardiac or vas-
cular dysfunction, or both [23]. Previous studies demon-
strated that the myocardium can generate more force
after treatment with P188 [9,21]. This study also
demonstrates improved cardiac function after P188
treatment. However, we do not see a corresponding
effect in blood pressure. Thus, there is likely still an
undetermined vascular component to decreased systolic
blood pressures in mice that was not compensated for
at this level of improved cardiac function. This supports
previous literature that shows that mdx mice have
abnormal vascular endothelium responses and blood
pressure regulation [24,25].
This study did not show an improvement in skeletal
muscle specific force using in vitro measurements. Ng
et al. (2008) found that P188 addition to the muscle
bathing solution reduced the force deficit in the isolated,
whole lumbrical muscle [26]. Previous studies also
showed that P188 restored compliance to isolated car-
diac myocytes in solution, but these studies utilized
acute administration of P188. When myocytes were
used after a P188 washout period, properties returned to
those of untreated animals [9,21]. We did not measure
P188 serum levels and cannot estimate peak levels of
exposure. While benefits were seen in cardiac function,
no significant improvements in skeletal muscle function
or cardiac fibrosis were seen in this study secondary to
the chronic, intermittent dosing schedule. Thus, there is
mounting evidence that P188 is most effective during
acute administration in both cardiac and skeletal
muscle.
Conclusion
This study reports important pre-clinical data that
chronic intraperitoneal administration of P188 to mdx
mice stressed with subcutaneous isoproterenol can
potentially improve cardiac systolic function. Previous
studies support a role for acute treatment of P188 in
stressed dystrophin deficient animal models [9,21].
These results support further study of daily P188 ther-
apy in DMD patients. P188 could also prevent cardiac
damage in times of acute stress, including orthopedic
surgeries, respiratory failure and decompensated heart
failure with a continuous, intravenous infusion. As
advances in the treatment of DMD skeletal muscle
pathology continue, it is as important to also develop
cardiac muscle therapies so that DMD patients do not
increasingly succumb to cardiac failure [27]. Based on
these findings, P188 acute and chronic therapy may pro-
vide benefits for patients with Duchenne muscular dys-
trophy and further studies are encouraged.
Additional material
Additional file 1: In vitro muscle testing data for the extensor
digitorum longus (EDL) in female mdx mice exposed to
isoproterenol and treated with P188 over 2 and 4 weeks and
compared with untreated female mdx mice of the same age. There
are no significant differences between groups. This file contains data
obtained from in vitro muscle force testing of the EDL in female mdx
mice exposed to isoproterenol and treated with P188 over 2 and 4
weeks and compared with untreated female mdx mice of the same age.
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